Beclomethasone Dipropionate (DB00394): A Comprehensive Monograph

Executive Summary

Beclomethasone Dipropionate (BDP), identified by DrugBank ID DB00394 and CAS Number 5534-09-8, is a second-generation synthetic, chlorinated glucocorticoid that functions as a potent anti-inflammatory agent.[1] It operates as a prodrug, undergoing rapid hydrolysis by esterase enzymes in tissues to its highly active metabolite, Beclomethasone 17-Monopropionate (17-BMP). This active metabolite exerts strong, localized anti-inflammatory effects through high-affinity binding to glucocorticoid receptors, modulating gene expression to suppress inflammatory pathways.[1]

The primary therapeutic applications of BDP include the long-term maintenance and prophylactic treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD), where it is used both as a monotherapy and as a component of combination treatments.[4] It is also widely indicated for the management of seasonal and perennial allergic rhinitis, the prevention of nasal polyp recurrence, and the treatment of various corticosteroid-responsive dermatoses.[4] To meet these diverse clinical needs, BDP is available in multiple formulations, including pressurized metered-dose inhalers (pMDI), dry powder inhalers (DPI), breath-actuated inhalers (BAI), aqueous nasal sprays, and topical creams.[4]

A key advantage of BDP's pharmacological design is its ability to deliver potent therapeutic action at the local site of inflammation while minimizing systemic absorption and the associated adverse effects—a significant improvement over earlier, systemically administered corticosteroids.[1] The drug is generally well-tolerated; common side effects are typically localized and include oral candidiasis (thrush) and pharyngitis with inhaled use, which can often be mitigated by rinsing the mouth after administration.[4] However, the use of high doses or long-term therapy carries a risk of systemic corticosteroid effects, such as hypothalamic-pituitary-adrenal (HPA) axis suppression, decreased bone mineral density, and reduced growth velocity in pediatric populations.[3]

The therapeutic landscape for BDP continues to evolve. Current research and development efforts are focused on advanced formulations, such as those with extrafine particles that enhance drug deposition in the small airways, and its use as a foundational component in single-inhaler triple therapies (SITT) that combine BDP with a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) for the management of severe respiratory diseases.[10]

Introduction to Beclomethasone Dipropionate

Beclomethasone Dipropionate (BDP) represents a cornerstone in the modern management of chronic inflammatory airway diseases. First patented in 1962 and introduced for medical use in 1972, BDP was a landmark development in corticosteroid therapy, gaining its first approval for use in the United States in 1976.[4] Its introduction marked a pivotal shift in the treatment paradigm for conditions like asthma, moving away from reliance on systemic corticosteroids with their significant side effect burden towards targeted, localized therapy.

Chemically, BDP is a diester of beclomethasone, a synthetic corticosteroid that is structurally analogous to dexamethasone.[1] It is classified as a second-generation, chlorinated glucocorticoid and more specifically as a 3-oxo-Δ¹,Δ⁴-steroid.[1] The therapeutic rationale behind its development was to engineer a molecule with high topical anti-inflammatory potency that could be delivered directly to the site of inflammation—such as the lungs or nasal mucosa—while minimizing the systemic adverse effects commonly associated with earlier oral corticosteroids like prednisolone.[1] When administered intranasally, BDP has been reported to be less irritating to the nasal mucosa and to possess a longer duration of action compared to its predecessors.[1]

The therapeutic utility of BDP is derived from its potent anti-inflammatory, anti-allergic, and antipruritic properties, which have established it as a first-line therapy for a range of chronic inflammatory conditions.[1] Its importance in global health is underscored by its inclusion on the World Health Organization's List of Essential Medicines.[4]

The development of BDP was more than a simple chemical modification; it embodied a fundamental change in therapeutic philosophy. Prior to its availability, controlling severe asthma often necessitated long-term treatment with systemic corticosteroids, which exposed patients to a high risk of debilitating side effects such as Cushing's syndrome, osteoporosis, and adrenal suppression.[9] The innovation of BDP was twofold: its potent local activity and a pharmacokinetic profile designed for rapid inactivation upon systemic absorption. As a prodrug, BDP is delivered to the site of inflammation where it is converted to its highly active metabolite, 17-BMP.[3] Any portion of the drug that is swallowed and absorbed through the gastrointestinal tract is subject to extensive first-pass metabolism in the liver, effectively clearing it before it can exert significant systemic effects.[14] This "local action, low systemic impact" profile allowed, for the first time, for the effective long-term prophylactic control of airway inflammation. This transformed asthma management from a reactive approach, focused on treating acute attacks, to a proactive strategy centered on preventing the underlying inflammation, a principle that now forms the basis of modern asthma care.[1]

Physicochemical Properties and Molecular Identification

A comprehensive understanding of Beclomethasone Dipropionate's pharmacological behavior begins with its fundamental physicochemical properties. As a solid, white to creamy-white odorless powder, BDP's molecular structure and properties are key determinants of its formulation, delivery, and biological activity.[1]

Systematic Nomenclature and Molecular Identifiers

The molecule is precisely defined by standardized chemical nomenclature and identifiers. Its International Union of Pure and Applied Chemistry (IUPAC) name isphenanthren-17-yl]-2-oxoethyl] propanoate.[1] Its formal chemical name is 9-chloro-11β-hydroxy-16β-methyl-17,21-bis(1-oxopropoxy)-pregna-1,4-diene-3,20-dione.[2]

Key structural and molecular identifiers include a molecular formula of C28​H37​ClO7​ and a molecular weight of approximately 521.04 g/mol.[2] Its structure is unambiguously represented by its InChI and InChIKey identifiers, which are essential for database cross-referencing and computational chemistry applications.[1]

Physical Properties

BDP exhibits physical properties that are critical to its pharmaceutical development. It has a reported melting point in the range of 208-210 °C, although some sources note a lower range of 117-120 °C, a discrepancy that may be attributable to different polymorphic forms or measurement techniques.[1] A defining characteristic is its poor solubility in water, measured at approximately 2.08e-03 g/L.[1] In contrast, it is soluble in various organic solvents, including acetone, chloroform, and short-chain alcohols, as well as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and ethanol at concentrations around 10 mg/ml.[2] This lipophilic nature is quantified by its partition coefficient (LogP) of 3.49, indicating a strong preference for lipid environments over aqueous ones.[1]

Table 1: Chemical and Physical Identifiers for Beclomethasone Dipropionate

Identifier Type	Value	Source(s)
DrugBank ID	DB00394	1
CAS Number	5534-09-8	1
IUPAC Name	phenanthren-17-yl]-2-oxoethyl] propanoate	1
Molecular Formula	C28​H37​ClO7​	2
Molecular Weight	521.04 g/mol	2
InChIKey	KUVIULQEHSCUHY-XYWKZLDCSA-N	1
SMILES	CCC(=O)OCC(=O)[C@]1(C@HC)OC(=O)CC
Physical Description	Solid; white to creamy-white odorless powder
Melting Point	208-210 °C
Water Solubility	2.08×10−3 g/L
LogP	3.49

The physicochemical profile of BDP is a double-edged sword that has profoundly influenced the trajectory of its pharmaceutical development. Its high lipophilicity, reflected in a LogP of 3.49, is essential for its therapeutic action, as it allows the molecule to readily diffuse across the lipid-rich cell membranes of airway and skin tissues to reach its intracellular target receptors. However, this same property is coupled with extremely poor water solubility, which presents a significant formulation challenge. A simple aqueous solution for inhalation is not feasible. This inherent insolubility necessitated the development of more complex delivery systems, starting with suspension-based pressurized metered-dose inhalers (pMDIs) and later evolving to solution-based pMDIs, such as Qvar, which utilize a cosolvent like ethanol to dissolve the drug.

This solubility challenge remains a primary driver of innovation. Modern research efforts are focused on advanced formulation strategies like nanosuspensions and solvent/anti-solvent precipitation methods, which aim to engineer BDP particles at the nanoscale to increase their surface area, thereby enhancing their dissolution rate and bioavailability upon administration. Adding another layer of complexity is BDP's propensity to form different crystalline structures, including hydrates and solvates, depending on the solvent used during manufacturing. These different solid-state forms can have varying stability and dissolution characteristics, requiring stringent control over the crystallization process to ensure consistent product performance. Consequently, the entire history of BDP formulation can be viewed as a continuous scientific endeavor to harness the therapeutic benefits of its lipophilicity while systematically overcoming the hurdles posed by its insolubility.

Comprehensive Pharmacological Profile

The clinical efficacy and safety of Beclomethasone Dipropionate are underpinned by a distinct pharmacological profile characterized by its action as a prodrug, its potent effects on inflammatory pathways, and a pharmacokinetic disposition designed to maximize local activity while minimizing systemic exposure.

Mechanism of Action

The therapeutic effects of BDP are not mediated by the parent molecule itself but by its active metabolite. BDP is a prodrug with a weak binding affinity for the glucocorticoid receptor (GR). Upon administration, particularly via inhalation, it is rapidly and extensively hydrolyzed by esterase enzymes present in the lungs and other tissues. This enzymatic action cleaves the propionate esters, primarily yielding Beclomethasone 17-Monopropionate (17-BMP), the principal active metabolite responsible for the drug's therapeutic effects.

The potency of 17-BMP is remarkable. In vitro studies have demonstrated that it possesses an exceptionally high binding affinity for the human GR. This affinity is approximately 13 times greater than that of the potent steroid dexamethasone, 6 times greater than triamcinolone acetonide, and 25 times greater than that of the parent BDP molecule. This high-affinity binding is the initiating step in a cascade of molecular events.

Once 17-BMP binds to the GR in the cytoplasm, the activated receptor-ligand complex undergoes a conformational change, dimerizes, and translocates into the cell nucleus. Inside the nucleus, it exerts its anti-inflammatory effects through two primary genomic pathways:

1. Transactivation: The complex binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs). This binding upregulates the transcription of genes that code for anti-inflammatory proteins, such as lipocortin-1 (also known as annexin A1) and interleukin-10 (IL-10), which play key roles in resolving inflammation.
2. Transrepression: The activated GR complex interferes with the activity of pro-inflammatory transcription factors, most notably Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1). It achieves this, in part, by recruiting histone deacetylases to the sites of active gene transcription. This action reverses the histone acetylation that normally opens up chromatin, causing the DNA to coil more tightly and thus reducing the access of NF-κB and AP-1 to their target genes. This effectively represses the expression of a wide array of pro-inflammatory genes, including those for cytokines, chemokines, and adhesion molecules.

Pharmacodynamics

The pharmacodynamic effects of BDP are the clinical manifestation of its molecular mechanism. By modulating gene expression, BDP (via 17-BMP) effectively attenuates the complex inflammatory responses characteristic of asthma, allergic rhinitis, and dermatoses. It achieves this by suppressing the recruitment, activation, and function of multiple key inflammatory cells, including mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils. Furthermore, it inhibits the release of potent inflammatory mediators from these cells, such as histamine, eicosanoids (prostaglandins and leukotrienes), and various cytokines that perpetuate the inflammatory cascade.

A central tenet of BDP's pharmacodynamic profile is the favorable ratio of local to systemic activity. When inhaled, it acts primarily at the site of deposition in the lungs, leading to improved lung function, decreased airway hyper-reactivity, and a reduction in asthma symptoms. However, it is crucial to recognize that some systemic absorption is unavoidable. Chronic use, particularly at high doses, can lead to systemic corticosteroid effects. These can be evaluated by monitoring pharmacodynamic markers such as the function of the hypothalamic-pituitary-adrenal (HPA) axis, which is known to be suppressed in a dose-dependent manner, as well as markers of bone turnover and, in pediatric patients, growth velocity.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of BDP and its active metabolite 17-BMP is intricately designed to facilitate potent local action with controlled systemic exposure.

Absorption: The route of administration significantly influences absorption.

• Inhaled Route: Following inhalation, a fraction of the dose is deposited in the lungs, from where it is absorbed into the systemic circulation. A substantial portion, however, deposits in the oropharynx, is swallowed, and is absorbed from the gastrointestinal tract. Systemic exposure is therefore a composite of both pulmonary and oral absorption. Pharmacokinetic studies show variability, likely due to differences in delivery devices and study designs. One study of a 320 mcg inhaled dose reported a peak plasma concentration (Cmax) for BDP of 88 pg/mL reached at a Tmax of 0.5 hours, while the Cmax for the active metabolite 17-BMP was 1419 pg/mL at a Tmax of 0.7 hours. A separate intravenous study provided pharmacokinetic parameters after inhalation, noting a BDP Cmax of 35,356 pg/mL at a Tmax of 0.2 hours, underscoring the rapid absorption from the lungs.
• Oral/Swallowed Route: The swallowed fraction of an inhaled dose undergoes extensive first-pass metabolism. The absolute oral bioavailability of 17-BMP (i.e., the fraction reaching systemic circulation after oral administration) is approximately 41%. It is estimated that this oral route contributes about 26% of the total systemic exposure to 17-BMP following an inhaled dose.
• Nasal Route: After intranasal administration, the systemic bioavailability of 17-BMP is approximately 44%.

Distribution: Once in the systemic circulation, BDP and 17-BMP exhibit different distribution characteristics. The parent drug, BDP, has a moderate steady-state volume of distribution (Vss) of 20 L. In contrast, the active metabolite, 17-BMP, distributes far more extensively into tissues, with a large Vss of 424 L. This extensive tissue distribution is consistent with its lipophilic nature and its role as the primary effector molecule at local sites. The protein binding of 17-BMP in plasma is high, in the range of 94-96%.

Metabolism: BDP is a classic prodrug that undergoes rapid and extensive metabolism. This conversion is mediated by esterase enzymes found ubiquitously in tissues, including the lung, liver, and gastrointestinal tract. The primary metabolic pathway is hydrolysis to the highly active 17-BMP. Minor metabolites, including beclomethasone-21-monopropionate (B-21-MP) and the fully hydrolyzed, inactive beclomethasone (BOH), are also formed. This rapid, pre-systemic conversion, especially within the lung, is a key feature of its pharmacology.

Excretion: Elimination of BDP and its metabolites occurs predominantly via the feces, with approximately 60% of an administered dose being excreted through this route. A smaller fraction, less than 12%, is excreted in the urine, primarily as conjugated polar metabolites. Renal clearance of the parent drug and its active metabolite is negligible.

Half-life: The elimination half-lives of BDP and 17-BMP are markedly different. Following intravenous administration, the parent drug BDP is cleared very rapidly, with a half-life (t1/2​) of only 0.5 hours. The active metabolite 17-BMP has a significantly longer terminal elimination half-life of approximately 2.7-2.8 hours, allowing for a more sustained therapeutic effect. The apparent half-life of 17-BMP is even longer following oral (8.8 hours) or intranasal (5.7 hours) administration, reflecting absorption-rate-limited elimination.

Table 2: Comparative Pharmacokinetic Parameters of BDP and 17-BMP

Parameter	Analyte	Route	Value	Source(s)
Cmax	BDP	Inhaled (320 mcg)	88 pg/mL
	17-BMP	Inhaled (320 mcg)	1419 pg/mL
	BDP	IV (1000 mcg)	35356 pg/mL
	17-BMP	IV (1000 mcg)	2633 pg/mL
	17-BMP	Oral (4000 mcg)	703 pg/mL
	17-BMP	Intranasal	310 pg/mL
Tmax	BDP	Inhaled (320 mcg)	0.5 h
	17-BMP	Inhaled (320 mcg)	0.7 h
	BDP	IV (1000 mcg)	0.2 h
	17-BMP	IV (1000 mcg)	0.2 h
	17-BMP	Oral (4000 mcg)	4.0 h
AUC	BDP	IV (1000 mcg)	6660 pg·h/mL
	17-BMP	IV (1000 mcg)	6185 pg·h/mL
t½ (elimination)	BDP	IV	0.5 h
	17-BMP	IV	2.7 h
Vss	BDP	IV	20 L
	17-BMP	IV	424 L
Clearance	BDP	IV	150 L/h
	17-BMP	IV	120 L/h
Bioavailability (%F)	17-BMP	Oral	41%
	17-BMP	Intranasal	44%
	17-BMP	Inhaled (Lung)	36%

The pharmacokinetic data reveal a finely tuned system designed to maximize the therapeutic index—the ratio of local efficacy to systemic toxicity. BDP itself acts as a transient delivery vehicle. Its rapid systemic clearance (150 L/h) and very short half-life (0.5 hours) ensure that the parent prodrug does not accumulate in the circulation. The true therapeutic agent, 17-BMP, is generated

in situ within the target tissue, such as the lung. Once formed, 17-BMP's pharmacokinetic properties—a much larger volume of distribution (424 L) and a longer half-life (2.7 hours)—allow it to penetrate tissues effectively and exert a sustained local anti-inflammatory effect. The balance between lung bioavailability (which drives efficacy) and oral bioavailability of the swallowed fraction (which contributes to systemic side effects) is critical. This understanding provides a strong scientific rationale for the development of advanced inhalation technologies, such as extrafine particle aerosols. By increasing the fraction of the dose deposited in the lungs and reducing the amount deposited in the oropharynx, these technologies can directly improve the therapeutic index, boosting local efficacy while simultaneously reducing the systemic load and the potential for adverse effects.

Clinical Applications and Therapeutic Efficacy

Beclomethasone Dipropionate is a versatile and widely prescribed corticosteroid with established efficacy across a spectrum of inflammatory diseases. Its clinical use is defined by specific indications, a variety of formulations tailored to different target organs, and evidence-based dosing guidelines derived from extensive clinical trials.

Approved Indications and Formulations

BDP is approved for a range of conditions, primarily targeting respiratory and dermatological inflammation.

• Asthma: It is a cornerstone for the long-term maintenance treatment and prophylaxis of asthma in adults and children. The specific age approval varies by product, typically for patients aged 4 or 5 years and older. It is crucial to note that BDP is a preventer medication intended for regular use to control underlying inflammation and is not indicated for the rapid relief of an acute asthma attack or bronchospasm.
• Chronic Obstructive Pulmonary Disease (COPD): BDP is used in the long-term management of COPD, frequently as a component of fixed-dose combination therapies to reduce inflammation and exacerbation frequency.
• Allergic Rhinitis: Aqueous nasal spray formulations are indicated for the prophylaxis and treatment of symptoms associated with seasonal and perennial allergic rhinitis (hay fever), such as sneezing, runny nose, and nasal itching.
• Nasal Polyps: Nasal sprays are also used to treat nasal polyps and to help prevent their recurrence following surgical removal.
• Dermatoses: Topical cream formulations are available for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive skin conditions, including various forms of dermatitis and psoriasis.
• Ulcerative Colitis: An oral pill formulation has been developed and used for the treatment of ulcerative colitis, leveraging its local anti-inflammatory action within the gastrointestinal tract.

To serve these diverse indications, BDP is available in numerous formulations, including inhalation aerosols (pMDI), breath-actuated inhalers (BAI), dry powder inhalers (DPI), aqueous nasal sprays, topical creams, and oral tablets.

Dosing Regimens and Administration Guidelines

Dosing of BDP is highly individualized based on the indication, patient age, disease severity, and the specific product formulation.

• Inhaled for Asthma (e.g., QVAR®, QVAR® Redihaler™):
• Adults and Adolescents (≥12 years): The typical starting dose is 40 to 80 mcg inhaled twice daily. This dose can be titrated upwards based on clinical response to a maximum recommended dose of 320 mcg twice daily.
• Children (4 or 5 to 11 years): The usual starting dose is 40 mcg inhaled twice daily. The dose may be increased if necessary, but the maximum dose is generally 80 mcg twice daily.
• Administration: Proper inhaler technique is critical for efficacy. Patients should be counseled to rinse their mouth with water and spit it out after each use to minimize the risk of developing oral candidiasis (thrush). New inhalers, or those that have not been used for an extended period, require priming with test sprays before use.
• Nasal Spray for Allergic Rhinitis (e.g., QNASL®):
• Adults and Adolescents (≥12 years): The standard dose is two sprays (80 mcg per spray) in each nostril once daily, for a total daily dose of 320 mcg.
• Children (4 to 11 years): The recommended dose is one spray in each nostril once daily, for a total daily dose of 160 mcg.
• Combination Inhalers (e.g., BDP/formoterol):
• For maintenance therapy, the usual dose is one or two puffs twice a day. For certain asthma management plans (e.g., Maintenance and Reliever Therapy, or MART), the combination inhaler may also be used as needed for symptom relief, with a total daily limit, for example, of 8 puffs.

Table 3: Dosing Guidelines for Beclomethasone Dipropionate by Indication and Formulation

Indication	Patient Population	Formulation/Brand Example	Initial Dose	Maximum Dose	Administration Notes	Source(s)
Asthma	Adults & Children ≥12 yrs	QVAR® pMDI / Redihaler™	40-80 mcg BID	320 mcg BID	Rinse mouth with water after use. Not for acute attacks.
	Children 4/5-11 yrs	QVAR® pMDI / Redihaler™	40 mcg BID	80 mcg BID	Monitor growth. Rinse mouth after use.
Allergic Rhinitis	Adults & Children ≥12 yrs	QNASL® Nasal Spray	160 mcg (2 sprays) per nostril OD	320 mcg total daily	For nasal use only. Prime before first use.
	Children 4-11 yrs	QNASL® Nasal Spray	80 mcg (1 spray) per nostril OD	160 mcg total daily	For nasal use only.
Asthma/COPD	Adults	BDP/Formoterol Combo Inhaler	1-2 puffs BID	Up to 8 puffs total per day in some asthma plans	Can be used as preventer and reliever in specific plans.

OD = once daily; BID = twice daily

Summary of Clinical Trial Evidence

The efficacy of BDP is supported by a wealth of clinical trial data across its major indications.

• Persistent Asthma: Multiple Phase 3, randomized, controlled trials have established the superiority of BDP over placebo for improving lung function, as measured by the forced expiratory volume in one second (FEV1​). Studies such as NCT02513160 and NCT02040779 have demonstrated the efficacy and safety of various BDP formulations, including both standard pMDIs and breath-actuated inhalers, in adolescent and adult patients. Furthermore, a dose-ranging study focusing on an extrafine BDP formulation concluded that a dose of 200 µg twice daily offered the optimal balance of efficacy and safety for patients whose asthma was poorly controlled on lower doses of inhaled corticosteroids (ICS).
• COPD: Clinical trials have increasingly focused on the role of BDP within combination therapies. Studies like NCT03627858 and NCT03963167 have evaluated BDP as part of fixed-dose triple therapies with a LABA (formoterol) and a LAMA (glycopyrronium), demonstrating effectiveness in improving outcomes in real-world settings for patients with severe COPD.

The clinical effectiveness of BDP is not solely a function of the molecule itself but is inextricably linked to the sophistication of its delivery device and formulation. The historical evolution from standard-sized particles in early inhalers to the development of modern extrafine particle formulations has fundamentally altered the drug's dose-response relationship. Early BDP inhalers delivered particles that deposited predominantly in the larger, central airways. The transition to hydrofluoroalkane (HFA) propellants enabled the creation of solution-based aerosols, like Qvar, which produce extrafine particles. These smaller particles have a much greater capacity to travel into and deposit within the small, peripheral airways. This is of profound clinical importance, as inflammation in these small airways is now recognized as a major contributor to asthma symptoms, airflow limitation, and poor disease control.

As a direct consequence of this improved peripheral deposition, a lower nominal dose of an extrafine BDP formulation can achieve a therapeutic effect equivalent to, or greater than, a higher dose of a conventional, non-extrafine formulation. This principle is reflected in clinical practice guidelines and prescribing information, which explicitly state that doses between older chlorofluorocarbon (CFC)-based inhalers and newer HFA-based extrafine inhalers are not interchangeable on a microgram-for-microgram basis. This necessitates that clinicians be acutely aware of the specific BDP product being prescribed to ensure appropriate dosing. This dynamic also provides the rationale for developing patient-friendly devices like breath-actuated inhalers (BAIs). While shown to be bioequivalent to standard pMDIs, BAIs improve drug delivery for patients who struggle with the hand-breath coordination required for pMDIs, thereby enhancing real-world effectiveness by ensuring the advanced formulation is delivered to the lungs correctly.

Safety, Tolerability, and Risk Management

The safety profile of Beclomethasone Dipropionate is well-characterized and is central to its clinical utility. As a topical corticosteroid, it is designed to maximize local therapeutic effects while minimizing systemic toxicity. However, a comprehensive risk assessment requires consideration of both common local side effects and the potential for systemic effects, particularly with long-term or high-dose use.

Adverse Effects Profile

The adverse effects of BDP are largely dependent on the route of administration and the total systemic exposure.

• Common Local Effects:
• Inhaled Formulations: The most frequently reported local side effects include oropharyngeal candidiasis (a yeast infection commonly known as thrush), headache, sore throat (pharyngitis), and dysphonia (hoarseness or difficulty speaking). Upper respiratory tract infections and cough may also occur. The risk of oral candidiasis can be significantly reduced by counseling patients to rinse their mouth with water and spit after each inhalation.
• Nasal Formulations: Common local effects include nasal irritation, a burning sensation, dryness, stuffy or runny nose, and epistaxis (nosebleeds). While rare, there have been reports of nasal septal perforation and localized infections with Candida albicans in the nose or throat following long-term use.
• Serious Systemic Effects: These effects are characteristic of the corticosteroid class and are associated with prolonged use and/or high doses, which lead to significant systemic absorption.
• HPA Axis Suppression: Chronic administration can suppress the body's natural production of cortisol, leading to adrenal insufficiency. This is a critical consideration when tapering patients off systemic oral steroids onto inhaled BDP.
• Immunosuppression: BDP can suppress the immune system, leading to an increased risk of infections. It may also cause a more serious or even fatal course of varicella (chickenpox) or measles in susceptible individuals who are not immunized or have not been previously exposed.
• Ocular Effects: Long-term use is associated with an increased risk of developing glaucoma, increased intraocular pressure (IOP), and cataracts. Blurred vision has also been reported.
• Bone Effects: Systemic corticosteroid exposure can lead to a decrease in bone mineral density (BMD), increasing the risk of osteoporosis and fractures.
• Growth Effects in Pediatrics: A key concern in children is the potential for a reduction in growth velocity. It is recommended that the growth of pediatric patients receiving long-term BDP therapy be monitored regularly.
• Other Systemic Effects: Rare but serious effects include the development of Cushing's syndrome, mood and personality changes (particularly with oral formulations), exacerbation of psychiatric disturbances, and very rare cases of Kaposi's sarcoma associated with prolonged corticosteroid therapy.

Contraindications, Warnings, and Precautions

• Contraindications: BDP is contraindicated in patients with a known hypersensitivity to the drug or any of its formulation components. It is also contraindicated for the primary treatment of status asthmaticus or other acute episodes of asthma where intensive medical intervention is required.
• Warnings and Precautions: A critical warning is that BDP is not a bronchodilator and should not be used for the immediate relief of acute bronchospasm; a short-acting beta-agonist should be used for this purpose. Rarely, BDP can cause paradoxical bronchospasm, an immediate worsening of wheezing after inhalation, which requires immediate discontinuation of the drug and treatment with a rescue inhaler. Caution is advised when prescribing BDP to patients with active or quiescent tuberculosis or other untreated systemic or localized infections.

Drug-Drug Interactions

BDP is susceptible to both pharmacokinetic and pharmacodynamic interactions.

• Pharmacokinetic Interactions: BDP is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Co-administration with potent inhibitors of CYP3A4, such as ritonavir and ketoconazole, can significantly increase the systemic concentrations of BDP and its metabolites. This elevates the risk of systemic corticosteroid side effects, and such combinations should be used with caution.
• Pharmacodynamic Interactions: The glucocorticoid effects of BDP can lead to hyperglycemia, potentially reducing the efficacy of antidiabetic agents like acarbose and acetohexamide. When used concurrently with non-steroidal anti-inflammatory drugs (NSAIDs) such as aceclofenac or acetylsalicylic acid, there may be an increased risk of gastrointestinal irritation and ulceration. Combining BDP with other immunosuppressive agents, like abatacept, can potentiate the risk of infection.

Table 4: Clinically Significant Drug-Drug Interactions with Beclomethasone Dipropionate

Interacting Drug/Class	Potential Effect	Mechanism	Clinical Recommendation	Source(s)
Potent CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Abametapir)	Increased serum concentration of BDP and its metabolites; increased risk of systemic side effects.	Pharmacokinetic (Inhibition of CYP3A4 metabolism)	Use with caution. Monitor for signs of systemic corticosteroid effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Aceclofenac, Acetylsalicylic acid)	Increased risk of gastrointestinal irritation and bleeding.	Pharmacodynamic (Additive GI toxicity)	Monitor for gastrointestinal adverse effects.
Antidiabetic Agents (e.g., Acarbose, Acetohexamide)	Increased risk of hyperglycemia; potential reduction in efficacy of antidiabetic agent.	Pharmacodynamic (Glucocorticoid-induced hyperglycemia)	Monitor blood glucose levels closely. Dose adjustment of antidiabetic agent may be necessary.
Other Immunosuppressants (e.g., Abatacept)	Increased risk of infection due to additive immunosuppressive effects.	Pharmacodynamic (Additive immunosuppression)	Monitor for signs and symptoms of infection.
Loop/Thiazide Diuretics	Potential for enhanced hypokalemia.	Pharmacodynamic (Glucocorticoid mineralocorticoid effect)	Monitor serum potassium levels.

Use in Special Populations

• Pregnancy: While the inhaled form of BDP is generally regarded as safe during pregnancy, comprehensive data are lacking. There are no adequate and well-controlled studies in pregnant women. BDP is listed by California's Proposition 65 as a substance known to cause developmental toxicity. The clinical decision must balance the significant risks of uncontrolled asthma to both the mother and fetus against the potential risks of the medication.
• Lactation: It is not known for certain whether BDP or its metabolites are excreted in human milk, although other corticosteroids are. The decision to breastfeed while using BDP should consider the clinical need of the mother and the potential benefits of breastfeeding against any potential adverse effects on the child.
• Pediatrics: The efficacy and safety of BDP have been established for specific products in defined pediatric age groups (e.g., QVAR RediHaler for ages ≥4 years). The primary safety concern is the potential for dose-dependent suppression of growth velocity, which necessitates regular monitoring of growth in children on long-term therapy and using the lowest effective dose.

A nuanced interpretation of the safety data reveals a potential for clinical confusion stemming from an "information gap." BDP is primarily marketed and understood as a "local" therapy with a favorable safety profile due to low systemic absorption. However, the official prescribing information contains an extensive list of warnings and precautions regarding systemic effects that are identical to those for oral corticosteroids, including HPA axis suppression, osteoporosis, and cataracts. This creates an apparent contradiction: is it a safe local drug or a systemic drug delivered locally? The reality is that it is both, and the risk profile exists on a continuum that depends on the dose, duration of therapy, patient susceptibility, and, critically, the efficiency of the delivery device. The evolution to extrafine particle formulations, while increasing therapeutic efficacy in the small airways, may also lead to greater alveolar deposition and subsequent systemic absorption, potentially increasing systemic risk at a given nominal dose. This complexity means clinicians cannot view all BDP products as interchangeable. It mandates a high level of vigilance for systemic side effects, especially when using high doses, newer high-efficiency inhalers, or when treating vulnerable populations like children. The "local action" branding, while accurate in principle, may inadvertently foster a false sense of security if not carefully balanced with the comprehensive warnings.

Manufacturing, Synthesis, and Regulatory Landscape

The journey of Beclomethasone Dipropionate from chemical synthesis to a globally available medication involves complex manufacturing processes and navigation through stringent regulatory frameworks in different jurisdictions.

Chemical Synthesis and Manufacturing

The synthesis of BDP is a multi-step chemical process. A route described in patent literature (CN111944002A) outlines a modern approach starting from a steroid precursor, designated as compound DB11. The key stages of this synthesis are:

1. Macrocyclization and Ring-Opening: The process begins with the reaction of the DB11 precursor with an orthopropionate (such as triethyl orthopropionate) in the presence of an acid catalyst like p-toluenesulfonic acid. This is followed by a ring-opening step using an aqueous solution of aluminum trichloride.
2. Acylation (Propionylation): The intermediate from the previous step undergoes acylation to add the two propionyl groups at the C17 and C21 positions. This is achieved using a propionylation reagent, such as propionic anhydride, and a catalyst like 4-dimethylaminopyridine (DMAP) or triethylamine.
3. Final Ring-Opening and Purification: A final ring-opening reaction is conducted using hydrochloric acid at low temperatures. Following this, the organic layer containing the product is separated, washed, and concentrated. The crude BDP is then purified, typically through recrystallization, to yield the final active pharmaceutical ingredient (API).

Manufacturing BDP presents several challenges. Historically, synthetic routes have been plagued by inconsistent yields, byproduct formation, and the use of now-obsolete or hazardous reagents, complicating both laboratory- and industrial-scale production. Consequently, significant research has focused on process optimization to develop more efficient, cost-effective, scalable, and environmentally friendly ("green") synthesis methodologies. An important aspect of manufacturing is the final crystallization step, as the choice of solvent can significantly influence the final product's physical properties. Depending on the solvent system, the process can yield either the desired anhydrous form of BDP or various solvates (e.g., ethanol solvate) or hydrates, which have different crystalline structures and may impact the stability and performance of the final drug product. Advanced manufacturing techniques, such as solvent/anti-solvent precipitation, are also being explored to produce BDP nanoparticles with improved dissolution characteristics directly, bypassing traditional milling steps.

Regulatory History and Status

BDP has a long and complex regulatory history, with different formulations and indications being approved by major agencies over several decades.

• United States (Food and Drug Administration - FDA):
• 1976: First approved for medical use in the United States.
• September 15, 2000: Approval of Qvar® (NDA 020911), a pMDI with a hydrofluoroalkane (HFA) propellant and an extrafine solution formulation. This was a significant milestone, marking a transition away from older chlorofluorocarbon (CFC) inhalers.
• March 23, 2012: Approval of QNASL® Nasal Aerosol for the treatment of allergic rhinitis. This approval was later expanded in December 2014 to include pediatric patients.
• May 23, 2014: Approval of a new version of Qvar® that included an integrated dose counter.
• August 2017: Approval of QVAR® RediHaler™ (NDA 207921), a breath-actuated inhaler (BAI) designed to simplify administration.
• orBec® (Oral): An application for oral BDP for the treatment of gastrointestinal Graft-versus-Host Disease (GVHD) was submitted. However, the FDA issued a "Not Approvable" letter in October 2007, and the product did not gain approval in the US.
• European Union (European Medicines Agency - EMA):
• Clenil® (Nebuliser Suspension): This product underwent a formal Article 30 referral procedure to harmonize its prescribing information across EU member states where it was nationally approved. The Committee for Medicinal Products for Human Use (CHMP) issued a final opinion on September 15, 2016, leading to a harmonized indication and dosing regimen, which was adopted by the European Commission on November 11, 2016.
• Trimbow®/Trydonis® (Triple Therapy): The fixed-dose combination of BDP, formoterol, and glycopyrronium received marketing authorisation for COPD in July 2017 (Trimbow®) and April 2018 (Trydonis®). The indication was later expanded to include asthma.
• orBec® (Oral): The marketing authorisation application for orBec® for GVHD was formally withdrawn by the sponsor on May 22, 2008. The withdrawal occurred after the CHMP had expressed significant concerns and issued a provisional opinion that the drug could not have been approved based on the data submitted.
• Japan (Pharmaceuticals and Medical Devices Agency - PMDA):
• The provided research materials do not contain specific approval dates or history for BDP products in Japan. The documents from the PMDA discuss general approval processes and lists of recently approved drugs that do not include BDP, indicating a gap in the available data for this specific region.

The divergent regulatory outcomes for the oral formulation, orBec®, in the US and EU are particularly telling. Both the FDA and EMA ultimately found the evidence supporting its use for gastrointestinal GVHD to be insufficient, despite the high unmet medical need in this orphan disease population. The main clinical study involved only 129 patients, which may have been underpowered to definitively demonstrate a favorable risk-benefit profile to the satisfaction of these major regulatory bodies. This situation underscores the high evidentiary bar required for drug approval, even for a molecule with a well-understood mechanism of action when applied to a new, complex, and heterogeneous disease. It highlights that even with an orphan drug designation, robust clinical data are paramount.

Global Brand Name Compendium

Beclomethasone Dipropionate is marketed globally under a multitude of brand names, reflecting its widespread use and the variety of available formulations.

Table 5: International Brand Names and Formulations

Brand Name	Formulation	Market/Region (if known)	Source(s)
Qvar® / Qvar® RediHaler™	pMDI / BAI	US, Europe
Clenil®	pMDI / Nebuliser Suspension	Europe
Beconase® / Beconase AQ®	Nasal Spray	US, Europe
QNASL®	Nasal Aerosol	US
Beclovent®	pMDI (largely discontinued)	US
Vanceril®	pMDI (largely discontinued)	US
Foster®	pMDI (with Formoterol)	Europe
Trimbow® / Trydonis®	pMDI (with Formoterol, Glycopyrronium)	Europe
Aerocort	Inhaler (with Salbutamol)	India
Beclate	Inhaler, Rotacaps	India
Azbec	pMDI	Bangladesh
Decomit	pMDI	Bangladesh

Advanced Topics and Future Directions

The development of Beclomethasone Dipropionate has moved beyond the optimization of the molecule itself and is now focused on the frontiers of drug delivery, novel therapeutic applications, and its role as a foundational element in advanced combination therapies.

Innovations in Drug Delivery Systems

The clinical performance of BDP is intimately tied to how effectively it is delivered to its target site. Research in this area has led to significant advancements.

• Extrafine Particle Formulations: A major breakthrough was the transition from CFC-based suspension inhalers to HFA-based solution aerosols. This enabled the creation of "extrafine" particle formulations, such as in Qvar®, with a mass median aerodynamic diameter (MMAD) of approximately 1.1 µm, compared to 3.5 µm for older inhalers. These smaller particles can penetrate deeper into the respiratory tract, achieving significantly higher deposition in the small, peripheral airways. This is clinically crucial, as small airway inflammation is a key driver of asthma pathology. This technology has also been applied to dry powder inhalers (DPIs), such as the NEXThaler™, providing an alternative delivery platform for extrafine BDP.
• Breath-Actuated Inhalers (BAI): To address the common problem of poor patient coordination with traditional pMDIs, breath-actuated devices like the QVAR® RediHaler™ were developed. These devices automatically release the medication upon patient inhalation, ensuring more reliable drug delivery. Pharmacokinetic studies have confirmed that these BAI devices are bioequivalent to their pMDI counterparts, offering improved ease of use without compromising drug exposure.
• Sustained-Release and Nanotechnology: The cutting edge of BDP delivery research involves re-engineering the drug at the particle level to modify its therapeutic profile.
• Sustained-Release Powders: Researchers are developing inhalable dry powders by encapsulating BDP within biodegradable polymeric microparticles. These formulations are designed to provide a controlled, sustained release of the drug within the lungs over an extended period. This approach has the potential to reduce dosing frequency from twice daily to perhaps once daily or less, which could dramatically improve patient adherence and overall disease management.
• Nanosuspensions: To overcome BDP's poor water solubility, nanotechnology is being employed to create nanosuspensions. In this technique, BDP is formulated into nanocrystals with diameters in the range of 200-240 nm. These tiny particles have a vastly increased surface-area-to-volume ratio, which significantly improves their dissolution rate and bioavailability. These nanosuspensions can be delivered via modern nebulizers and are even being explored for delivery via novel platforms, such as modified electronic cigarette technology, as a potential alternative to conventional inhalers.

Emerging and Investigational Uses

While well-established in respiratory medicine, the potent local anti-inflammatory properties of BDP have led to its investigation for other inflammatory conditions.

• Eosinophilic Esophagitis (EoE): EoE is an allergic inflammatory disease of the esophagus characterized by dense eosinophilic infiltration. Swallowed topical corticosteroids are a primary treatment. BDP is being actively investigated for this indication. A completed Phase 1 clinical trial (NCT01016223) evaluated the effect of swallowed BDP on various inflammatory markers in adult patients with EoE. A subsequent pilot, placebo-controlled crossover study demonstrated that an 8-week course of swallowed BDP significantly reduced esophageal eosinophil counts and improved symptoms of dysphagia compared to placebo, providing strong proof-of-concept for this application. This represents a highly promising future indication for BDP.
• Graft-versus-Host Disease (GVHD): An oral formulation of BDP (orBec®) was developed to treat gastrointestinal GVHD, a severe complication of hematopoietic stem cell transplantation. The rationale was to deliver the steroid topically to the inflamed gut mucosa to reduce inflammation with minimal systemic side effects. Despite this compelling rationale and an orphan drug designation, the drug failed to gain approval from either the FDA or EMA, as the clinical trial data were deemed insufficient to establish a favorable risk-benefit profile.

Role in Combination Therapies

Perhaps the most significant evolution in the use of BDP is its integration into multi-drug combination products, which now represent the standard of care for moderate-to-severe respiratory diseases.

• Dual Therapy (ICS/LABA): Fixed-dose combinations of BDP with a Long-Acting Beta-Agonist (LABA), such as formoterol (e.g., Foster®), are a mainstay of asthma treatment for patients not adequately controlled on an ICS alone. The two components work synergistically: the ICS (BDP) treats the underlying inflammation, while the LABA provides long-acting bronchodilation. Corticosteroids may also help prevent the development of tolerance to LABAs by upregulating β2-receptor gene expression.
• Single-Inhaler Triple Therapy (SITT): The latest advance is the development of SITT, which combines three drug classes in a single device: an ICS (BDP), a LABA (formoterol), and a Long-Acting Muscarinic Antagonist (LAMA), such as glycopyrronium (e.g., Trimbow®, Trydonis®).
• Rationale: For patients with severe, uncontrolled asthma or COPD, the addition of a LAMA provides an additional mechanism of bronchodilation by blocking cholinergic pathways. This triple-pronged approach has been shown to be more effective at improving lung function and, critically, reducing the frequency of disease exacerbations compared to dual therapy.
• Clinical Evidence: Large-scale clinical trials, such as the TRIMARAN and TRIGGER studies, have provided robust evidence for the efficacy and safety of extrafine BDP/formoterol/glycopyrronium triple therapy in patients with uncontrolled asthma.
• Adherence and Cost-Effectiveness: A major advantage of SITT is the simplification of complex treatment regimens. By consolidating three separate medications into a single inhaler, SITT is expected to significantly improve patient adherence, a major challenge in chronic disease management. Economic analyses have also suggested that this approach is cost-effective compared to open triple therapy (using multiple inhalers).

The trajectory of BDP's development illustrates a broader trend in pharmaceutical science. The focus has shifted from the discovery and optimization of the molecule itself to the engineering of the therapeutic platform. BDP has become a reliable, well-understood anti-inflammatory backbone upon which more complex and effective therapeutic systems are built. Initial research centered on BDP's basic pharmacology. This was followed by decades of work to optimize its delivery to the lungs, progressing from basic CFC inhalers to advanced extrafine particle HFA and DPI devices. Today, the most advanced research treats BDP's efficacy as a given. The innovation lies in combining it with other active agents like formoterol and glycopyrronium in a single, highly engineered drug-device combination, or in completely re-imagining its physical form through nanotechnology to alter its release profile and bioavailability. BDP has successfully transitioned from being the "star" molecule to being the indispensable "foundation" of advanced respiratory therapeutics.

Expert Analysis and Concluding Recommendations

Beclomethasone Dipropionate has cemented its place in the therapeutic armamentarium as a highly relevant and effective corticosteroid. Its enduring success is attributable to a well-characterized efficacy profile, a favorable ratio of local-to-systemic activity, and remarkable versatility across multiple inflammatory diseases, formulations, and delivery platforms. The evolution of BDP serves as a compelling case study in pharmaceutical lifecycle management, demonstrating how a mature molecule can remain at the forefront of therapy by being adapted into progressively more sophisticated drug-device combination products and novel delivery systems.

Synthesis of Therapeutic Profile

The core strength of BDP lies in its design as a potent prodrug that is activated locally, thereby maximizing its anti-inflammatory effects at the target site while minimizing systemic side effects. This principle has made it a first-line treatment for chronic respiratory diseases like asthma and COPD for decades. Compared to older systemic steroids, its therapeutic index for topical administration is vastly superior. When compared to other modern inhaled corticosteroids (ICS), the choice of agent often depends less on inherent differences in molecular efficacy and more on factors such as the characteristics of the delivery device, patient preference and ability to use the device correctly, and formulary or cost considerations. The continuous innovation in its formulation, particularly the development of extrafine particle aerosols, has maintained its competitiveness and relevance in a crowded therapeutic class.

Knowledge Gaps and Future Research Directions

Despite its long history of use, several key questions remain, pointing to important areas for future research.

1. Long-Term Safety of Advanced Formulations: Extrafine particle formulations are demonstrably more efficient at delivering BDP to the entire lung, including the peripheral airways where it can be readily absorbed into the systemic circulation. While this enhances efficacy, it raises a critical question: does this increased systemic absorption carry a greater long-term risk of systemic side effects (e.g., on bone density or adrenal function) compared to conventional formulations at therapeutically equivalent doses? Long-term, prospective observational studies and real-world evidence analyses are needed to address this crucial safety question.
2. Head-to-Head Trials of Novel Delivery Systems: The pipeline for BDP includes exciting new platforms like sustained-release polymeric particles and nebulized nanosuspensions. To justify their place in therapy, these systems must be rigorously compared against established, high-efficiency inhalers (e.g., extrafine pMDIs and DPIs) in head-to-head clinical trials. These studies should evaluate not only traditional endpoints like lung function but also patient-centered outcomes such as adherence, quality of life, and real-world exacerbation rates.
3. Establishing a Role in Eosinophilic Esophagitis (EoE): The pilot data for swallowed topical BDP in EoE are promising. The next essential step is to conduct larger, well-powered, multicenter Phase 3 trials to definitively establish its efficacy and safety in this population. Such studies should also aim to determine the optimal formulation (e.g., swallowed aerosol vs. a viscous slurry) and dosing regimen for inducing and maintaining remission.
4. Refining Pediatric Safety Data: The potential for growth suppression in children remains a primary concern with all ICS, including BDP. As newer, more efficient delivery devices become more common in pediatric practice, continued pharmacovigilance and dedicated clinical studies are essential to understand the long-term impact on final adult height and bone health, and to refine dosing recommendations to ensure the lowest effective dose is always used.

Concluding Statement

Beclomethasone Dipropionate has successfully navigated a remarkable evolutionary path, from a pioneering topical steroid that revolutionized asthma care to a foundational component of today's most advanced respiratory therapies. Its future relevance is secure, not through the reinvention of its own mechanism, but through its seamless integration into increasingly sophisticated drug-device combination products and innovative drug delivery platforms. These next-generation systems, built upon the reliable efficacy of BDP, are poised to address the remaining challenges in the management of severe, chronic inflammatory diseases of the airways and beyond.

Works cited

1. Beclomethasone Dipropionate | C28H37ClO7 | CID 21700 - PubChem, accessed July 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Beclomethasone-Dipropionate
2. Beclomethasone Dipropionate (CAS 5534-09-8) - Cayman Chemical, accessed July 31, 2025, https://www.caymanchem.com/product/38880/beclomethasone-dipropionate
3. Beclomethasone dipropionate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00394
4. Beclometasone - Wikipedia, accessed July 31, 2025, https://en.wikipedia.org/wiki/Beclometasone
5. Beclomethasone dipropionate Completed Phase N/A Trials for Chronic Obstructive Pulmonary Disease (COPD) | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00394/clinical_trials?conditions=DBCOND0031289&status=completed
6. Beclomethasone - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 31, 2025, https://www.pediatriconcall.com/drugs/beclomethasone/310
7. Beclomethasone Metered Dose Inhaler (MDI) - Cleveland Clinic, accessed July 31, 2025, https://my.clevelandclinic.org/health/drugs/20771-beclomethasone-metered-dose-inhaler-mdi
8. Beclomethasone Oral Inhalation: MedlinePlus Drug Information, accessed July 31, 2025, https://medlineplus.gov/druginfo/meds/a681050.html
9. Beclomethasone inhaled: Side Effects, Uses, Dosage, Interactions ..., accessed July 31, 2025, https://www.rxlist.com/beclomethasone_inhaled/generic-drug.htm
10. Full article: Efficacy and safety of inhaled extrafine beclomethasone dipropionate in adults with asthma: a randomized, parallel-group, dose-ranging study (BEAM) - Taylor & Francis Online, accessed July 31, 2025, https://www.tandfonline.com/doi/full/10.1080/02770903.2021.1928184
11. Extrafine formulation of beclomethasone dipropionate/formoterol ..., accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/40219730/
12. Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12033506/
13. go.drugbank.com, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00394#:~:text=Beclomethasone%20dipropionate%20works%20by%20attenuating,lymphocytes%2C%20macrophages%2C%20and%20neutrophils.
14. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2014471/
15. Beclomethasone (inhalation route) - Side effects & dosage - Mayo ..., accessed July 31, 2025, https://www.mayoclinic.org/drugs-supplements/beclomethasone-inhalation-route/description/drg-20113003
16. BECONASE AQ - (beclomethasone dipropionate, monohydrate) Nasal Spray, 42 mcg, accessed July 31, 2025, https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Beconase_AQ/pdf/BECONASE-PI-PIL.PDF
17. Beclomethasone Dipropionate - OEHHA - CA.gov, accessed July 31, 2025, https://oehha.ca.gov/chemicals/beclomethasone-dipropionate
18. Beclomethasone Dipropionate | CAS 5534-09-8 | SCBT - Santa Cruz Biotechnology, accessed July 31, 2025, https://www.scbt.com/p/beclomethasone-dipropionate-5534-09-8
19. [Beclomethasone Dipropionate (200 mg)] - CAS [5534-09-8] - USP Store, accessed July 31, 2025, https://store.usp.org/product/1048506
20. Preparation of Ultrafine Beclomethasone Dipropionate Drug Powder by Antisolvent Precipitation | Industrial & Engineering Chemistry Research - ACS Publications, accessed July 31, 2025, https://pubs.acs.org/doi/10.1021/ie0615537
21. Preparation and Characterization of Beclomethasone Dipropionate Solvates | Crystal Growth & Design - ACS Publications, accessed July 31, 2025, https://pubs.acs.org/doi/10.1021/acs.cgd.8b00465
22. The History of Therapeutic Aerosols: A Chronological Review - PMC - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5278812/
23. A green route to beclomethasone dipropionate nanoparticles via solvent anti-solvent precipitation by using subcritical water as, accessed July 31, 2025, https://scholar.harvard.edu/files/danwang/files/2017-a_green_route_to_beclomethasone_dipropionate_nanoparticles_via_solvent_anti-solvent_precipitation_by_using_subcritical_water_as_the_solvent.pdf
24. Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma - MDPI, accessed July 31, 2025, https://www.mdpi.com/2075-1729/12/4/596
25. BECLOMETHASONE - Inxight Drugs, accessed July 31, 2025, https://drugs.ncats.io/drug/KGZ1SLC28Z
26. New Developments in Corticosteroids | Proceedings of the American Thoracic Society, accessed July 31, 2025, https://www.atsjournals.org/doi/10.1513/pats.200402-007MS
27. Beclomethasone Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 31, 2025, https://www.drugs.com/dosage/beclomethasone.html
28. How and when to use beclometasone inhalers - NHS, accessed July 31, 2025, https://www.nhs.uk/medicines/beclometasone-inhalers/how-and-when-to-use-beclometasone-inhalers/
29. Beclomethasone (nasal route) - Side effects & dosage - Mayo Clinic, accessed July 31, 2025, https://www.mayoclinic.org/drugs-supplements/beclomethasone-nasal-route/description/drg-20075573
30. Beclomethasone - brand name list from Drugs.com, accessed July 31, 2025, https://www.drugs.com/ingredient/beclomethasone.html
31. Beclomethasone dipropionate - American Chemical Society, accessed July 31, 2025, https://www.acs.org/molecule-of-the-week/archive/b/beclomethasone-dipropionate.html
32. Beclomethasone dipropionate Completed Phase 3 Trials for Persistent Asthma Treatment, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00394/clinical_trials?conditions=DBCOND0046502&phase=3&purpose=treatment&status=completed
33. Randomized trial to assess the efficacy and safety of beclomethasone dipropionate breath-actuated inhaler in patients with asthma - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/29317015/
34. EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT00394368
35. Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/28937845/
36. 207921Orig1s000 - accessdata.fda.gov, accessed July 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207921Orig1s000OtherR.pdf
37. CN111944002A - Beclomethasone dipropionate intermediate and preparation method thereof - Google Patents, accessed July 31, 2025, https://patents.google.com/patent/CN111944002A/en
38. Practical and scalable synthesis of beclomethasone dipropionate - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/356772417_Practical_and_scalable_synthesis_of_beclomethasone_dipropionate
39. Drug Approval Package: Qvar (Beclomethasone Dipropionate) NDA #020911, accessed July 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-911_Qvar.cfm
40. QNASL (beclomethasone dipropionate) FDA Approval History ..., accessed July 31, 2025, https://www.drugs.com/history/qnasl.html
41. Teva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose Counter, accessed July 31, 2025, https://www.tevausa.com/news-and-media/press-releases/teva-received-fda-approval-for-qvar-beclomethasone-dipropionate-hfa-with-dose-counter/
42. OrBec (beclomethasone dipropionate): What is it and is it FDA approved? - Drugs.com, accessed July 31, 2025, https://www.drugs.com/history/orbec.html
43. Clenil and associated names - referral | European Medicines ..., accessed July 31, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/clenil-associated-names
44. Beclometasone/formoterol/glycopyrronium bromide - Wikipedia, accessed July 31, 2025, https://en.wikipedia.org/wiki/Beclometasone/formoterol/glycopyrronium_bromide
45. Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD, accessed July 31, 2025, https://www.chiesi.com/en/chiesi-group-receives-european-marketing-authorisation-for-its-triple-combination-therapy-inhalation-powder-beclometasone-dipropionate-formoterol-fumarate-dihydrate-and-glycopyrronium-in-extrafine-fixed-formulation-delivered-through-nexthaler-for-the-trea
46. orBec | European Medicines Agency (EMA), accessed July 31, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/orbec
47. KEGG DRUG: New Drug Approvals in Japan, accessed July 31, 2025, https://www.genome.jp/kegg/drug/br08318.html
48. First approval of generic dry powder inhaler drug products in Japan - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/32613551/
49. List of Approved Products | Pharmaceuticals and Medical Devices Agency - PMDA, accessed July 31, 2025, https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
50. Review Reports: Drugs | Pharmaceuticals and Medical Devices Agency - PMDA, accessed July 31, 2025, https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html
51. en.wikipedia.org, accessed July 31, 2025, https://en.wikipedia.org/wiki/Beclometasone#:~:text=Clenil%2C%20Qvar%2C%20Cortis%20are%20brandnames,the%20nasal%20spray%20or%20aerosol.
52. Beclomethasone - Guide to Brand or Trade Names - Medindia, accessed July 31, 2025, https://www.medindia.net/drugs/trade-names/beclomethasone.htm
53. Beclomethasone Dipropionate (Inhaler) | List of Available Brand Names with Prices in Bangladesh | MedEx, accessed July 31, 2025, https://medex.com.bd/generics/109/beclomethasone-dipropionate-inhaler/brand-names
54. Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study - MDPI, accessed July 31, 2025, https://www.mdpi.com/2075-4426/12/2/146
55. Sustained-Release Powders Based on Polymer Particles for Pulmonary Delivery of Beclomethasone Dipropionate in the Treatment of Lung Inflammation - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10144675/
56. Delivery of beclomethasone dipropionate nanosuspensions with an electronic cigarette | Request PDF - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/348726949_Delivery_of_beclomethasone_dipropionate_nanosuspensions_with_an_electronic_cigarette
57. A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT01016223
58. Beclomethasone dipropionate Completed Phase 1 Trials for Eosinophilic Esophagitis, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00394/clinical_trials?conditions=DBCOND0000863&phase=1&status=completed
59. Effect of topical beclomethasone on inflammatory markers in adults with eosinophilic esophagitis: A pilot study - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5468761/
60. Study Details | Study of orBec® as Monotherapy in the Treatment of ..., accessed July 31, 2025, https://clinicaltrials.gov/study/NCT01925950
61. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma - PubMed Central, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5933614/
62. Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT00497237
63. Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report - Frontiers, accessed July 31, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1357362/full